Skip to content

A Comparison of Distribution between Six Incobotulinum Toxin Type A concentration in Forehead Hyperhidrosis Patients; A Pilot Study

A Comparison of Distribution between Six Incobotulinum Toxin Type A concentration in Forehead Hyperhidrosis Patients; A Pilot Study

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
TCTR
Registry ID
TCTR20210825006
Enrollment
36
Registered
2021-08-25
Start date
2021-03-25
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

forehead hyperhidrosis hyperhidrosis botulinumtoxinA incobotulinumtoxinA

Interventions

injected with this dose once,injected with this dose once,injected with this dose once,injected with this dose once,injected with this dose once,injected with this dose once
IncobotulinumtoxinA 1:1 concentration,IncobotulinumtoxinA 1:2 concentration,IncobotulinumtoxinA 1:2.5 concentration,IncobotulinumtoxinA 1:4 concentration,IncobotulinumtoxinA 1:5 concentration,Incobotu

Sponsors

Division of Dermatology, Department of medicine, Faculty of Medicine, Ramathibodi hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: participants who have homogeneous forehead hyperhidrosis following iodine starch test

Exclusion criteria

Exclusion criteria: The exclusion criteria included: (i) open wound or scar at face, (ii) uncontrolled inflammation/infection or other skin diseases on the face, (iii) immunocompromised status, (iv) history of skin cancer or keloids, (v) history of light/laser therapy or other facial procedures at forehead within 3 months prior to the study, (vi) history of systemic vitamin A and its derivatives treatment within 3 month prior to the study, (vii) history of botulinum toxin or filler injection within 1 year prior to the study, (viii) neuromuscular disorder and/or (ix) pregnant or lactation

Design outcomes

Primary

MeasureTime frame
area of anhodrosis 2nd and 4th week after injection image J program

Secondary

MeasureTime frame
side effect 2nd week and 4th week after injection asking the participants

Countries

Thailand

Contacts

Public ContactVasanop Vachiramon

Faculty of Medicine, Ramathibodi hospital

Vasanop@gmail.com0946369165

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026